Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ:POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.
Related news for (POAI)
- Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
- 24/7 Market News Snapshot 29 September, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
- Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
- UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)